R
Rik Vandenberghe
Researcher at Allen Institute for Brain Science
Publications - 430
Citations - 26622
Rik Vandenberghe is an academic researcher from Allen Institute for Brain Science. The author has contributed to research in topics: Frontotemporal dementia & Medicine. The author has an hindex of 69, co-authored 355 publications receiving 21180 citations. Previous affiliations of Rik Vandenberghe include Northwestern University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Noun and knowledge retrieval for biological and non-biological entities following right occipitotemporal lesions.
Rose Bruffaerts,An-Sofie De Weer,Sophie De Grauwe,Miek Thys,Eva Dries,Vincent Thijs,Stefan Sunaert,Mathieu Vandenbulcke,Simon De Deyne,Gerrit Storms,Rik Vandenberghe +10 more
TL;DR: This is the first lesion-based evidence of a critical contribution of the right medial fusiform cortex to tool naming, and dissociations along the dimension of attribute type during feature generation do not co-occur with category-specificity during naming in the current patient sample.
Journal ArticleDOI
Replication study of plasma proteins relating to Alzheimer's pathology
Liu Shi,Laura Winchester,Sarah Westwood,Alison L. Baird,Sneha N Anand,Noel J. Buckley,Abdul Hye,Nicholas J. Ashton,Nicholas J. Ashton,Isabelle Bos,Isabelle Bos,Stephanie J.B. Vos,Mara ten Kate,Philip Scheltens,Charlotte E. Teunissen,Rik Vandenberghe,Silvy Gabel,Karen Meersmans,Sebastiaan Engelborghs,Sebastiaan Engelborghs,Ellen De Roeck,Kristel Sleegers,Giovanni B. Frisoni,Olivier Blin,Jill C. Richardson,Régis Bordet,José Luis Molinuevo,Lorena Rami,Anders Wallin,Petronella Kettunen,Magda Tsolaki,Frans R.J. Verhey,Alberto Lleó,Isabel Sala,Julius Popp,Julius Popp,Gwendoline Peyratout,Pablo Martinez-Lage,Mikel Tainta,Peter Johannsen,Yvonne Freund-Levi,Yvonne Freund-Levi,Lutz Frölich,Valerija Dobricic,Cristina Legido-Quigley,Cristina Legido-Quigley,Frederik Barkhof,Ulf Andreasson,Ulf Andreasson,Kaj Blennow,Kaj Blennow,Henrik Zetterberg,Johannes Streffer,Christina M. Lill,Christina M. Lill,Lars Bertram,Lars Bertram,Pieter Jelle Visser,Pieter Jelle Visser,Hartmuth C. Kolb,Vaibhav A. Narayan,Simon Lovestone,Simon Lovestone,Alejo J. Nevado-Holgado +63 more
TL;DR: In this paper, the authors sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the "ATN" (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis.
Journal ArticleDOI
The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia.
TL;DR: A multidimensional approach to cognitive decline is explored, where amyloid plaque burden is situate among a number of other relevant dimensions, such as aging, volume loss, other proteinopathies such as TDP43 and Lewy bodies, and functional reorganisation of cognitive brain systems.
Journal ArticleDOI
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort
Sarah Westwood,Alison L. Baird,Sneha N Anand,Alejo J. Nevado-Holgado,Andrey Kormilitzin,Liu Shi,Abdul Hye,Nicholas J. Ashton,Nicholas J. Ashton,Angharad R. Morgan,Isabelle Bos,Stephanie J.B. Vos,Susan Baker,Noel J. Buckley,Mara ten Kate,Philip Scheltens,Charlotte E. Teunissen,Rik Vandenberghe,Silvy Gabel,Karen Meersmans,Sebastiaan Engelborghs,Sebastiaan Engelborghs,Ellen Elisa De Roeck,Ellen Elisa De Roeck,Kristel Sleegers,Giovanni B. Frisoni,Olivier Blin,Jill C. Richardson,Régis Bordet,José Luis Molinuevo,Lorena Rami,Anders Wallin,Petronella Kettunen,Magda Tsolaki,Frans R.J. Verhey,Alberto Lleó,Isabel Sala,Julius Popp,Julius Popp,Gwendoline Peyratout,Martinez-Lage P,Mikel Tainta,Peter Johannsen,Yvonne Freund-Levi,Yvonne Freund-Levi,Lutz Frölich,Valerija Dobricic,Cristina Legido-Quigley,Cristina Legido-Quigley,Lars Bertram,Lars Bertram,Frederik Barkhof,Henrik Zetterberg,B. Paul Morgan,Johannes Streffer,Johannes Streffer,Pieter Jelle Visser,Pieter Jelle Visser,Simon Lovestone,Simon Lovestone +59 more
TL;DR: These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74, and could significantly reduce the cost incurred to clinical trials through screen failure.
Journal ArticleDOI
In vivo amyloid imaging in cortical superficial siderosis.
Isabel Dhollander,Natalie Nelissen,Koen Van Laere,Dirk Peeters,Philippe Demaerel,Wim Van Paesschen,Vincent Thijs,Rik Vandenberghe +7 more
TL;DR: The findings suggest that SS in the context of β amyloidosis may have a distinct clinical and MRI signature, which may be otherwise clinically silent.